Inhibition of Wee1 is emerging as a novel therapeutic strategy for cancer, and some data suggest that cells with dysfunctional p53 are more sensitive to Wee1 inhibition combined with conventional chemotherapy than those with functional p53. We and others found that Wee1 inhibition sensitizes leukemia cells to cytarabine.
Introduction:
Cell cycle checkpoint and DNA damage response proteins are critical mediators of successful DNA replication in the presence and absence of genotoxic stress. Cancer cells are particularly dependent on these processes, a phenomenon that could be exploited therapeutically (1, 2). For example, Chk1 has been studied extensively as an adjuvant therapeutic target in combination with anti-cancer therapy, including radiation and chemotherapy (3, 4) . This strategy is expected to be particularly effective in tumors with disrupted p53 function, as they are highly dependent upon the G2/M checkpoint mediated by Chk1 (5).
Wee1 is a cell cycle checkpoint protein downstream of Chk1 that is activated during the normal cell cycle, as well as in the context of DNA damage. The primary function of WEE1 is inhibitory phosphorylation of CDKs at tyrosine 15 (Y15), thereby inhibiting cell cycle progression (6, 7) . Most studies of Wee1 have focused on the phosphorylation of CDK1 in the context of DNA damage, which prevents progression through mitosis with levels of DNA damage that would result in mitotic catastrophe. Like Chk1, inhibition of Wee1 in combination with DNA damaging agents has been explored as a therapeutic strategy for tumors with dysregulated p53.
Indeed, in published reports, inhibition of Wee1 with small-molecule inhibitors in combination with DNA damaging agents, including doxorubicin, has shown some specificity for TP53 mutated tumor models (8) (9) (10) (11) .
Using RNA interference screens, we and others have recently identified Wee1 as a critical mediator of AML cell survival after treatment with cytarabine, an antimetabolite that induces S-phase arrest, and a key component of successful AML therapy (12, 13) . The addition of the Wee1 inhibitor, MK1775 (8) , to cytarabine impairs the cell cycle checkpoint and induces more apoptosis than cytarabine alone (13) . Notably, our data were generated in cell lines that are reported to have normal p53 function.
Therefore, we sought to determine whether the function of p53 influences the sensitivity to Wee1 inhibition with chemotherapy in a broad panel of AML cell lines with various molecular abnormalities. In contrast to data from solid tumor models sensitized to DNA damaging agents (8) (9) (10) (11) , we found that the functionality of p53 has no bearing on the chemosensitization of AML cells to cytarabine, as all of the cell lines tested were sensitized to cytarabine with Wee1 inhibition. Mechanistic studies indicate that inhibition of Wee1 abrogates the S-phase checkpoint and augments apoptosis induced by cytarabine. Furthermore, in isogenic models, in which wildtype p53 activity was impaired by RNA-interference or dominant negative p53 constructs, we did not find enhanced chemosensitization with impaired p53. Also, in contrast with data from solid tumor models, we did not observe chemosensitization to doxorubicin with Wee1 inhibition in AML cells, even in cells with nonfunctional p53. In addition, we found that the chemosensitization to antimetabolite chemotherapeutics is not limited to leukemia, as lung cancer cells were equally sensitized to cytarabine and pemetrexed, whether p53 function was impaired or not. Lastly, in mice with AML, we found that the combination of Wee1 inhibition with cytarabine slowed disease progression and prolonged survival better than cytarabine alone. These data support the development of clinical trials of antimetabolite chemotherapeutics and Wee1 inhibition for patients with cancers; however, distinct from DNA damaging agents that induce the G2/M checkpoint, our data do not support the use of TP53 mutation as a biomarker to predict beneficial effects of Wee1 inhibition when combined with antimetabolites that induce the S-phase checkpoint. Kits (ABI) and confirmed to match published or internal databases as previously described (14) , prior to storage of stock vials in liquid nitrogen. All cells were cultured at 37°C in humidified air supplemented with 5% CO 2 , in RPMI supplemented with 10% FBS and antibiotics, except OCI-AML3 and Kasumi-1 which were cultured in RPMI supplemented with 20% heat-inactivated FBS. All AML cell lines were seeded at 1-2x10 5 /ml prior to experimentation. A549 cells were plated at 1-2.5x10 3 cells/well the day before experimentation. Cells were counted by propidium iodide (Sigma) exclusion and flow cytometry (Guava EasyCyte Plus, Millipore, Billerica, MA). Apoptosis and cell cycle were measured with the Guava EasyCyte Plus using the Guava Nexin and Guava Cell Cycle reagents per the manufacturer's protocol (Milipore).
Vectors: MSCV-ires-GFP (MiG), MSCV-DDp53-GFP (DDp53), and MSCV-DNp53-GFP (DNp53) plasmids (provided by Dr. DeGregori) were packaged into viral particles and transduced into OCI-AML3 cells as previously described (15) . Transduced cells were sorted for GFP using a MoFlow fluorescence activated cell sorter (Dako Cytomation, Carpinteria, CA). Non-silencing shRNA and shRNA targeting p53 from the TRC collection (16) were purchased from the Functional Genomics Facility of the University of Colorado Cancer Center (Boulder, CO) and packaged as previously described (17) . Transduced cells were selected in puromycin (Sigma-Aldrich, St. Louis, MO).
Antibodies, chemicals and reagents: Antibody directed against p21 CIP1 was purchased from BD Biosciences (San Jose, CA); antibodies against phosphorylated CDK1 (Y15), CDK2 (Y15), and histone H3 (S10) were purchased from Cell Signaling Technology (Danvers, MA). Cytarabine and doxorubicin were purchased from Sigma-Aldrich and diluted in water. Nutlin-3 was purchased from Cayman Chemical (Ann Arbor, MI) and diluted in DMSO. Pemetrexed was purchased from Selleck (Houston, TX Animal Studies: Female C57BL/6J mice, 6-8 weeks old, were purchased from The Jackson Laboratory (Bar Harbor, ME). All mice were housed in sterile micro-isolators in the Center for Comparative Medicine at the 
Results:
We previously reported synergistic inhibition of proliferation in AML cells with cytarabine and MK1775, a small molecule inhibitor of Wee1, in Molm13, MV4-11 and U937 cell lines (21) . These data suggested that the combinatorial effect of cytarabine and Wee1 inhibition in AML cells is independent of p53 functionality, FLT3 mutation, and MLL rearrangement (Supplemental Table 1 ). We sought to confirm this in a broader panel of AML cell lines with wild-type and mutated TP53, as well as other AML specific oncogenes (Supplemental Table 1 Table 1 ). Similar to findings in sarcoma cell lines (23), the mutational status of TP53 was not associated with sensitivity to MK1775 as a single agent (p=0.47;
Supplemental Table 1 and Supplemental Figure 1).
Despite single agent activity, MK1775 would most likely be incorporated into clinical trials as a chemosensitizing agent in combination with conventional chemotherapeutics. We chose OCI-AML3 and HL60 for detailed study of the chemosensitizing effects of Wee1 inhibition, as they reportedly have wild-type and mutated TP53, respectively (24, 25). To confirm the function of p53, we treated cells with nutlin-3a, a small molecule that interferes with the interaction of Mdm2 and p53, resulting in activation of p53 in cells in which it is not mutated (26). We found that OCI-AML3 cells were sensitive to treatment with nutlin-3a, while HL60 were not, consistent with the reported function of p53 in these cell lines ( Figure 1A) . As a second test of p53 function, we performed Western blotting for p21 induction with DNA damage induced by doxorubicin (27). As Figure 4C and Supplemental Figure 6 ). These data confirm that the synergistic anti-leukemic activity of cytarabine and MK1775 is independent of p53 functionality.
To determine if our observations are specific to AML, we tested the combination of cytarabine and MK1775 in the lung cancer derived A549 cell line. These cells have been described to have functional p53 (29), which we confirmed using nutlin-3a ( Figure 5A) . Consistent with our data in AML cell lines, A549 cells were synergistically sensitized to cytarabine when treated with MK1775 ( Figure 5B, Supplemental Figure 7) . We (Figure 6A) .
We then used an aggressive model of murine AML expressing MLL-ENL, FLT3-ITD and luciferase (18) , to determine if Wee1 inhibition would enhance the anti-leukemia effects of cytarabine. Consistent with the previous report (18) , cytarabine alone slowed the progression of the leukemia, as measured by luciferase expression over time ( Figure 6B and Supplemental Figure 8 ). The addition of MK1775 to cytarabine markedly enhanced the effects of cytarabine in slowing disease progression. Moreover, the addition of MK1775 to cytarabine significantly enhanced survival as compared to cytarabine alone ( Figure 6C) . including TP53 mutation, but also isogenic cell line models of AML and lung cancer. We also demonstrate that inhibition of Wee1 does not sensitize AML cells to doxorubicin, even when p53 function is disrupted. Thus, the use of TP53 mutation as a biomarker to predict likely responders to chemosensitization with MK1775 must be cautious and considered in the context of the chemotherapy with which it will be paired, as well as the preclinical data supporting the combination. Moreover, we demonstrate for the first time that Wee1 inhibition can be effectively combined with cytarabine to slow leukemia progression in vivo.
As noted, tumors with dysfunctional p53 may be particularly susceptible to the combination of MK1775 and DNA damaging agents (8) (9) (10) (11) , hypothetically due to the impaired G1 checkpoint and high dependence upon the G2/M checkpoint (5). The specificity of chemosensitization by MK1775 for TP53 mutated tumors was first reported in an ovarian cancer cell line (TOV21G) in which p53 had been knocked down by shRNA (8) . In these experiments, cells with knockdown of p53 had greater sensitization to gemcitabine, carboplatin and cisplatin as measured by sub-G1 DNA content, when treated with a single dose of MK1775 (8) . Conversely, lung cancer cells with impaired p53 function (H1299) transduced with inducible p53, were sensitized to ionizing irradiation with MK1775 if p53 was not expressed, but not sensitized when p53 expression was induced (9) . Other reports of the specificity of chemosensitization in TP53 mutated cell lines rely on data from non-isogenic cell lines (10, 11) . Notably, in a large panel of breast cell lines, while there was an association with mutated TP53 and synergy with gemcitabine and MK1775, many of the cell lines with mutated TP53 did not have CI values reflecting synergy, indicating that dysfunctional p53 does not always confer sensitivity to that particular combination (10) . Our data do not directly contradict these reports, as we have looked specifically in the context of antimetabolite chemotherapeutics with distinct mechanisms of action. Rather, our data highlight the function of Wee1 in the S-phase checkpoint activated by anti-metabolites (13), independent of p53, and broaden the potential clinical applicability of Wee1 inhibition. The fact that lung cancer cells were also sensitized to cytarabine and pemetrexed indicates that the beneficial effect of combining Wee1 inhibition with antimetabolite chemotherapeutics is not limited to AML and may be beneficial whether TP53 is mutated or not.
Importantly, we did not observe synergy with the anthracycline, doxorubicin, in combination with MK1775 in any of the AML cell lines tested. To the contrary, CI values suggested antagonism at some of the dose combinations tested. This information will be critical to consider in the design of clinical trials incorporating MK1775 into induction regimens for AML that typically include both cytarabine and an anthracycline.
Not surprisingly, we observed hematopoietic toxicity in mice treated with cytarabine with or without MK1775 when given daily for more than 5 days. Nonetheless, mice with leukemia survived longer due to enhanced disease control when treated with combination therapy as compared to cytarabine alone. Notably, we observed a decrease in disease burden with each course of combination therapy. Whether reducing the cytarabine dose and giving combined therapy continuously would be tolerable and more efficacious remains to be determined.
Taken together, these data suggest that the combination of Wee1 inhibition and cytarabine is a broadly applicable therapeutic strategy for AML, independent of several known molecular abnormalities, including mutation in TP53. Further, the inhibition of Wee1 in combination with other clinically relevant antimetabolites should be tested, as this strategy may be applicable across a number of different cancer types including lung cancer. While the use of TP53 mutation as a biomarker predictive of response for certain chemosensitization strategies may be appropriate, its use for combinations with antimetabolites appears to be limited. A. 
